Articles From: Amphenol Corporation Announces Record Fourth Quarter Results and New Stock Repurchase Program to AMRI to Present at the 33rd Annual J.P. Morgan Healthcare Conference


Amphenol Corporation (NYSE:APH) reported today fourth quarter 2014 diluted earnings per share excluding one-time items of $0.63 compared to $0.53 for the comparable 2013 period.
Sign-up for Amphenol Corporation Announces Record Fourth Quarter Results and New Stock Repurchase Program investment picks
2014/12/4
ENGLEWOOD, Colo.
Sign-up for Ampio Pharmaceuticals to present at the Oppenheimer Annual Healthcare Conference on December 11th, 2014 investment picks
2014/11/12
ENGLEWOOD, Colo.
Sign-up for Ampio updates status of clinical trials and manufacturing facility investment picks
Levi & Korsinsky is investigating the Board of Directors of AmREIT, Inc. (“AmREIT” or “the Company”) (NYSE:AMRE) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Edens Investment Trust.
Sign-up for AMRE INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation into the Board of Directors of AmREIT, Inc. Regarding the Fairness of the Sale of the Company to Edens Investment Trust -- AMRE investment picks
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of AmREIT, Inc. (NYSE:AMRE) (“AmREIT”) in connection with the sale of the Company to Edens Investment Trust.
Sign-up for AMRE SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of Directors of AmREIT, Inc. in Connection With the Fairness of the Sale of the Company to Edens Investment Trust – AMRE investment picks
AmREIT, Inc. (NYSE:AMRE) (“AmREIT” or the “Company”) today announced financial results for the third quarter ended September 30, 2014 and declared dividends for the fourth quarter ending December 31, 2014.
Sign-up for AmREIT Reports Third Quarter Results and Declares December 2014 Dividend investment picks
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of AmREIT, Inc. (“AmREIT”) (NYSE: AMRE) concerning the acquisition by Edens Investment Trust.
Sign-up for AmREIT Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Edens Investment Trust investment picks
AmREIT, Inc. (NYSE:AMRE) today announced that it has entered into a definitive agreement with Edens Investment Trust (“EDENS”) under which EDENS will acquire all outstanding shares of common stock of AmREIT for $26.55 per share in an all-cash transaction with a total enterprise value of approximately $763 million.
Sign-up for AmREIT to Be Acquired by EDENS for $26.55 Per Share investment picks
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of AmREIT, Inc. NEW YORK , Nov.
Sign-up for AMREIT, INC. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of AmREIT, Inc. (AMRE) Over the Proposed Sale of the Company to Edens Investment Trust investment picks
2014/11/5
WILMINGTON, Del.
Sign-up for AMREIT, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
2014/12/1
Rigrodsky & Long, P.A.: Do you own shares of AmREIT, Inc. (NYSE: AMRE )? Did you purchase any of your shares prior to October 31, 2014?
Sign-up for AMREIT, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
PRINCETON, N.J. , Dec.
Sign-up for AMREP Reports Second Quarter Fiscal 2015 Results investment picks
ALBUQUERQUE, N.M. , Nov.
Sign-up for AMRI Announces Albuquerque, N.M. Manufacturing Facility Fully Operational investment picks
ALBANY, N.Y. , Jan.
Sign-up for AMRI Announces CFO Transition investment picks
- Third quarter contract revenue of $57.5 million, up 8% from 2013 - Lower Discovery and API revenue is offset by addition of OsoBio - OsoBio business interruption contributes to third quarter adjusted loss per share of $(0.02) - Full year 2014 contract revenue expected to be between $253 and $261 million, an increase of 22% at the midpoint - Full year adjusted diluted EPS range between $0.67 and $0.73, compared to $0.70 in 2013 - Company provides initial 2015 outlook - Company creates new Drug Product reporting segment to reflect addition of OsoBio ALBANY, N.Y. , Nov.
Sign-up for AMRI Announces Third Quarter 2014 Results investment picks
ALBANY, N.Y. , Oct.
Sign-up for AMRI CEO to Present at the 2014 Credit Suisse Healthcare Conference investment picks
- 10-year Federal Contract Award Valued at up to $37 Million - ALBANY, N.Y. , Jan.
Sign-up for AMRI Receives NIH Contract Award for the Formulation Development and Manufacture of Pre-Clinical and Clinical Drug Product investment picks
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of investors who purchased Albany Molecular Research Inc. (“Albany Molecular” or the “Company”) (Nasdaq:AMRI) securities between August 5, 2014 and November 5, 2014.
Sign-up for AMRI SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Albany Molecular Research Inc. and Its Board of Directors and a Lead Plaintiff Deadline of January 12, 2015 investment picks
http://media.marketwire.com/attachments/201107/5424_LeviAndKorsinsky_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1165440&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for AMRI SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Albany Molecular Research Inc. and Its Board of Directors and a Lead Plaintiff Deadline of January 12, 2015 -- AMRI investment picks
- Significantly Expands AMRI's Analytical Services Capabilities and Extends Drug Product Development Services to include Sterile Injectable Formulation Development - ALBANY, N.Y. , Jan.
Sign-up for AMRI to Acquire Aptuit Drug Product Development and Aseptic Clinical Manufacturing Businesses investment picks
ALBANY, N.Y. , Oct.
Sign-up for AMRI to Announce Third Quarter Results on November 5, 2014 investment picks
ALBANY, N.Y. , Dec.
Sign-up for AMRI to Present at the 33rd Annual J.P. Morgan Healthcare Conference investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Amphenol Corporation Announces Record Fourth Quarter Results and New Stock Repurchase Program to AMRI to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent